Ekso Bionics (NASDAQ:EKSO) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a note issued to investors on Saturday. The firm set a “hold” rating on the stock.

EKSO has been the topic of a number of other research reports. Lake Street Capital dropped their target price on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. HC Wainwright lowered their price objective on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th.

Ekso Bionics Trading Down 10.2 %

Shares of NASDAQ:EKSO opened at $0.58 on Friday. Ekso Bionics has a fifty-two week low of $0.50 and a fifty-two week high of $3.13. The company has a market cap of $12.76 million, a PE ratio of -0.89 and a beta of 1.43. The company’s 50-day moving average price is $0.80 and its 200 day moving average price is $1.00. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The firm had revenue of $4.13 million during the quarter, compared to the consensus estimate of $6.00 million. During the same period in the prior year, the firm posted ($0.24) EPS. Sell-side analysts anticipate that Ekso Bionics will post -0.48 earnings per share for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.